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Abstract  Thrombotic  thrombocytopenic  purpura  (TTP)  is  a  disease  with  a  high  rate  of  mortality
if a  proper  treatment  is not  instated.  Plasmapheresis  with  plasmatic  exchange  is the  treatment
of choice.  Diagnosis  is performed  demonstrating  microangiopathic  hemolytic  anemia,  a  negative
direct  Coombs  test  and  thrombocytopenia.  Among  the  clinical  data,  neurological  and  renal
alterations  stand  out.  When  there  is a  reasonable  suspicion  in  the  diagnosis,  plasmapheresis
must be  initiated  immediately.  There  are different  diseases  that may  be similar  to  the  TTP
signs and  symptoms,  especially  in pregnant  women.  TTP  has a  high  risk  of  relapse  and  may
leave sequelae.
©  2016  Universidad  Auto´noma de Nuevo  Leo´n.  Published  by  Masson  Doyma  Me´xico  S.A. This  is
an open  access  article  under  the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Introduction
Eli  Moschowitz  was  the  first  to  describe  TTP,  when  per-
forming  the  autopsy  of a 16-year-old  girl  whom  he  had
treated.  During  this  autopsy,  Moschowitz  found  hyaline
thrombi  occluding  the  arterioles  and  capillaries,  he later
described  them  as  ‘‘aggregated  platelets’’.1 The  pres-
ence  of  hemolytic  anemia,  negative  Coombs,  schistocytes,
thrombocytopenia,  and high  lactate  dehydrogenase  (LDH)  in
patients  with  neurological  and/or  renal  alterations9 strongly
suggests  a  TTP diagnosis.
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versitario, ‘‘Dr José E. González’’, Universidad Autónoma de Nuevo
León, Av. Madero y Gonzalitos s/n, Col. Mitras Centro, Monterrey,
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TTP  has  a mortality  rate  of  90%  without  treatment.2 The
first  attempts  to  reduce  mortality  involved  large  doses  of
steroids.3 The  following  attempt  included  the use  of fresh
blood.4 Undoubtedly,  the turning  point  in TTP  treatment  was
the  use  of plasma,  which  first  took  place  in 1977.5 One  of the
greatest  progresses  concerning  the comprehension  of  the
physiopathology  of this  disease  was  to  identify  the  unusu-
ally  long  von Willebrand  factors  multimers,6 and  later,  to
identify  the deficiency  of the protease  in charge of  splitting
this  multimers  in congenital  TTP,7 and  lastly,  to identify  that
protease  as  the thirteenth  member  of  the  ADAMTS  family
(a  disintegrin  and  metalloproteinase  with  thrombospondin-1
repeats).8
Definition
Thrombotic  thrombocytopenic  purpura  (TTP)  is  a  pathology
which  puts  the  patient’s  life  in  danger,  with  a mortality  rate
http://dx.doi.org/10.1016/j.rmu.2015.10.001
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of  over  90%  when a  plasmapheresis  with  plasmatic  exchange
treatment  is  not  instated.  It  may  affect  multiple  systems  and
organs,  the  nervous  system  being  the one that  is  usually  the
most  affected.  Secondly,  it affects  the  renal  function  due
to  the  microthrombus  occluding  the  microvasculature.  It is
clinically  characterized  by  two  main  laboratory  alterations:
thrombocytopenia  and  microangiopathic  hemolytic  anemia.
Direct  Coombs  test  results  are  negative  and  LDH  is  invariably
increased.
Etiology
TTP  is  classified  according  to  its  etiology  (Chart  1),  although
TTP  can  be congenital,  as  a result  of  a mutation  of  the
gene  responsible  for desynthesizing  ADAMTS13.10 The  most
common  form  of TTP is  idiopathic  or  autoimmune,  where
antibodies  directed  against  ADAMTS13  are created.11
Pregnancy  is among  the  causes  of TTP,  even  though  diag-
nosis  in  these  cases  is  complicated  because  the clinical  and
laboratory  findings  are  very  similar  to  pregnancy-related
syndromes  like preeclampsia  and the HELLP  syndrome.  In
the  case  of  TTP,  the  signs and  symptoms  are  more  severe
and  the  quantification  of ADAMS-13  is  useful,  since  in other
pathologies  it is  usually  normal.12 Some  medications  have
been  linked  to  the appearance  of  TTP,  quinine  being  the
main  responsible.13 Clopidogrel,  ticlopidine,  cyclosporine  A
and  mitomycin  C,  among  others,  have  also  been  linked  as
TTP  triggers.14
Chemotherapy,  hematopoietic  stem  cell  transplants,  HIV,
and  lupus  are factors  frequently  related  to  TTP.  They  are,
however,  poorly  understood.  Hematopoietic  stem  cell post-
transplant  TTP  is  linked  to  the use  of  cyclosporine  A and  is
usually  a  severe  clinical  picture,  and  it is  difficult  to make
the  patient  enter  remission.15,16
Epidemiology
Young  women  are more  prone  to  this disease.  In  2005,
there  was  a  study  published  reporting  the incidence  of  TTP
and  hemolytic  uremic  syndrome  (HUS),  using  records  which
included  all  patients  sequentially  for  whom  plasmapheresis
treatment  is  requested  by  the  Oklahoma  Blood  Institute  due
to  clinical  suspicion  of  TTP  or  HUS,  based  on  the presence  of
microangiopathic  hemolytic  anemia  and  thrombocytopenia
without  an  apparent  etiology.
The incidence  rate  for  all patients  with  clinical  suspicion
of  TTP-HUS  in  the Oklahoma  records  was  11.29  per  mil-
lion  inhabitants.  The  incidence  rate  for  idiopathic  TTP-HUS
patients  was  4.6  per  million  inhabitants,  and  the  incidence
rate  for  patients  with  severe  ADAMTS13  deficiency  was  1.74
per  million  inhabitants.
The  incidence  rate  of TTP associated  with  severe
ADAMTS13  deficiency  is  over 9 times  higher  in black  people
than  other  races.  The  incidence  rate  of  TTP-HUS  comparing
women  with  men  was  >1.17
Physiopathology
The  main  histological  finding  in TTP is  hyaline  thrombi,
formed  by  platelet  aggregation.  These  thrombi  are
Table  1  Classification  of  TTP.
Type  Trigger
Congenital
(Upshaw--Shulman
syndrome)
Mutation  in the gene
responsible  for  synthesizing
ADAMTS13.
Acquired  or  idiopathic  Autoantibodies  against
ADAMTS13.
Related to  pregnancy
Drug-related  Clopidogrel,  ticlopidine.
HIV-related
Related  to  chemotherapy Cyclosporin  A, mitomycin  C.
Related  to
hematopoietic  stem
cell  transplant
Associated  with  the  use  of
cyclosporin  A
responsible  for  capillary  occlusion,  with  the subsequent
ischemia  in different  organs.1,18
The  von  Willebrand  Factor  (vWF)  plays a key role  in
platelet  aggregation.  VWF  produced  exclusively  in endothe-
lial  cells  and  platelets,  is  stored  as  Wiebel-Palade  granule  in
endothelial  cells  and  as -granule  in platelets.  Within  these
granules  it is  stored  in  an  ultra-large  shape  (ULvWF).7 After
being secreted,  ULvWF  attaches  to  the endothelial  surface.
The  longer  the  vWF  is,  the greater  the  effect  on  platelet
aggregation,  because  it is  more  related  to  the platelet’s  Ib
receptor.  The  role  of  ADAMTS13  is  to  split  the ULvWF  into
smallest  molecules.9,19 In congenital  TTP, ADAMTS13  activity
may  be lower  than  5%,  due  to  mutations  in the  gene  respon-
sible  for  ADAMTS13  production.10 Regarding  idiopathic  TTP,
findings  show that  it is  an  autoimmune  process,  mediated
by  IgG-class  antibodies.11 Even  though  ADAMTS13  deficiency
is  suggested  as  the  main  culprit,  it is important  to  men-
tion  the fact  that  other  causes  have  been studied,  such
as  lymphocytes,  macrophageactivation,  high  IL-1,  IL-6,  IL-2
and  TNF-  levels,  and  transforming  growth  factor  (TGF)-,
among  others.20,21
Signs, symptoms and laboratory findings
Classically,  a  pentad  is  described,  consisting  of  throm-
bocytopenia,  microangiopathic  hemolytic  anemia,  fever,
neurological  symptoms  and  renal  dysfunction.2 It is  worth
stressing  that  currently  this pentad is  rarely  seen, since
treatment  with  plasmapheresis  is  instated  before  it  occurs.
Nowadays,  the only  thing  required  is  thrombocytopenia  and
microangiopathic  hemolytic  anemia  in order  to  establish
diagnosis,  and, as mentioned  above,  the  presence  of  schis-
tocytes,  a negative  direct  Coombs  and  a high  LDH  confirm
clinical  suspicion  of  TTP  (Tables  1 and  2).
Clinical  findings  which  pave  the way  to  thrombocytopenia
suspicion  are  epistaxis,  menorrhagia,  hematuria,  gingivor-
rhagia,  etc.  Nevertheless,  significant  hemorrhage  data  is  not
necessarily  found,  as  in  the case  of  autoimmune  thrombocy-
topenic  purpura.  Platelets  are below normal  levels,  typically
less  than  20  ×  109/L.  Lab  work  shows  hemoglobin  below
normal  levels,  elevated  reticulocytes,  elevated  indirect
bilirubin,  elevated  LDH,  low haptoglobin,  normal  coagula-
tion  time,  usually  in early  stages  of  the disease,  and  a
negative  Coombs  direct  test  can also  be  used.  In  a  peripheral
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Table  2  Recommended  studies  for  patients  with  a  sus-
pected TTP  diagnosis.30
Recommended  study  Result  compatible  with  a  TTP
diagnosis
CBC  Anemia,  thrombocytopenia,
and  elevated  reticulocytes
Peripheral  blood  smear  Schistocytes
Clotting  times  Normal
DHL  Very  high
Liver  function  tests  Elevated  indirect  bilirubin
Urea  nitrogen,  creatinine. Renal  dysfunction
Direct  Coombs Negative
ADAMTS  13  (inhibitor,
activity,  antibody)
Do  not  wait  for  the  result  to
begin treatment.
Troponin  T,  EKG.  To  assess  myocardial  damage
HIV serology
CAT-scan  or  brain  MR  To  assess  neurological  damage
Pregnancy  test  (women)
blood  smear  we  are  able  to  observe  schistocytes  or  creno-
cytes  due  to  their mechanical  fragmentation  when going
through  occluded  capillaries.22,23
Regarding  nervous  system  symptoms,  in summary  these
are  the  focal  symptoms:  cephalalgia,  paresis,  aphasia,  cog-
nitive  deterioration,  and  transitory  ischemic  accidents.
Renal  dysfunction  is  not  as marked  as  hemolytic  uremic
syndrome,  and  rarely  requires  dialysis,24 though  proteinuria
and  oliguria,  among  others,  may  appear.  It  is  important  to
take  cardiac  affection  into  consideration.  This  is  typically
under  diagnosed,  and may  occur  in  acute  infarction,  con-
gestive  cardiac  failure,  arrhythmias,  cardiogenic  shock,  and
even  sudden  death.25,26 The  disease’s  natural  course  without
treatment  leads  to  death  for  90%  of  patients  in a matter  of
days.27
Differential diagnoses
Hemolytic  uremic syndrome  (HUS)
It  is usually  preceded  by  a  period  of  hemorrhagic  enterocoli-
tis  caused  by  the  shiga  toxin,  produced  by  diverse  serotypes
of  E.  coli  (i.e. 0157:H7)  or  Shigella  spp.,  particularly  in  chil-
dren.  HUS  is  a  disorder  in the  activation  of  a  complement,
in  order  to diagnose  it, it is  necessary  to  prove  the presence
of  the  shiga  toxin  and  for  the complement  to  be  depleted.
There  are  two  types  of  HUS,  the  typical  type which  occurs
in  children  and the  patient  usually  recovers  on his/her  own,
and  the  atypical,  which is  most  common  in adults.  Some-
times  there  is  no  diarrhea  or  a  clear  trigger  and  the  patient’s
course  with  renal  failure,  which  in  most  cases evolves  into
renal  failure  that  require  dyalisis.24,28
Preeclampsia
It  develops  in the  2nd  or  3rd  trimester,  with  the onset  of
hypertension  and proteinuria  after week  20 of  pregnancy.
Less  than  5%  of women  with  preeclampsia  will develop
severe  thrombocytopenia.12
HELLP  syndrome
Hemolysis,  Elevated  Liver  enzymes  and Low  Platelets
(HELLP).  A key point  in the  diagnosis  of  this  pathology  is
that  ADAMTS13  activity  is  normal.  Lab  work  shows  an  ele-
vation  of  LDH,  AST,  and  thrombocytopenia.  A LDH/AST  ratio
>22.12  suggests  that  a TTP diagnosis  is more  probable  than
HELLP  syndrome  in pregnant  patients  during  their  third
trimester.12,29
Diagnostic methods
Diagnosis  is  performed  through  clinical  history  and  the exam-
ination  of  a  peripheral  blood  smear.  The  measurement  of
ADAMTS13  levels  and  anti ADAMTS13  antibodies  is  recom-
mended;  however,  plasmapheresis  and  plasma  exchange
treatment  should  not  be delayed  while  waiting  for the
results  of these  measurements.  The  requirements  to begin
plasmapheresis  are merely  the  presence  of  schistocytes  in
peripheral  blood  (more  than  2 per  field),  anemia,  thrombo-
cytopenia  and  elevation  of LDH.
As  previously  pointed  out,  the  classic  pentad  of  clini-
cal  signs and  symptoms  is  no longer  considered  current;
nowadays  the presence  of  thrombocytopenia  and  microan-
giopathic  hemolytic  anemia  is  enough  to  create  the  suspicion
of  a TTP  diagnosis.  The  recommended  laboratory  tests  to
request  (chart  2) are useful  in order  to confirm  diagnostic
suspicion  of  TTP,  rule  out  differential  diagnoses  and  to  assess
white  organ  damage.30
Current treatment
Plasmapheresis  with  plasma  exchange  is  the treatment  of
choice.  This  therapy  should  begin  immediately  if there  is
the  suspicion  of  TTP.
Plasmapheresis  has  two main  objectives:
• Withdrawal  of the  ADAMTS13  inhibitor  (IgG),  as  well  as
most  of  the ULvWF  chains.
• Replacement  of deficient  or  missing  ADAMTS13.
Plasmapheresis  is  superior  to  plasma  infusion.31 How-
ever,  it  is  possible  to  use  a high  dose  of  plasma  infusion
(20--30  ml/kg/day)  as an initial therapy,  especially  when
there  is  no  access  to  resources  to  begin plasmapheresis,
and  even though  there  is the risk  of  a  volume  overload
and  proteinuria  exacerbation.  Plasma  infusion  is  not  a  sub-
stitute for plasmapheresis;  it just  functions  as  a bridge
therapy.32
The  exact duration  of  treatment  and  the  necessary
number  of sessions  is  highly  variable  between  patients,
depending  on  the presence  or  the title  of  the autoantibody
and  ADAMTS13  activity.
British guidelines  establish  plasmapheresis  to  be started
with  1.5 times  plasma  volume for  3  days,  and  reassess  the
patient  daily.  They  recommend  the use  of  plasma  treated
with  solvent/detergent  where  with  the risk  of  infections
and  adverse  immune  responses  decreases.30,33 The  exchange
volume  may  be lowered  to  1  if there  is clinical  and  lab
improvement.  Similarly,  it may  be increased  in cases  where
the patient’s  life  is  at risk.  At  our  center  plasmapheresis  is
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Suspicion of TTP (thrombocytopenia,
microangiopathic  hemolyt ic anemia,  and  very
high DH L) 
Take blood  samples before sta rting
plasmap heresis . 
Begin plasmapheresis with plasma exchange
at 1.5  vol umes f or the first  3 days,  then  1
volume until the patient stabilizes. Assess
rituximab,  es pecially in  sev ere  cases. 
Response:  >15  x 109/L plat elets ,
normal DH L, clinical improvem ent
for 2 days  in a  row  
Stop plasmapheresis,  eval uate
dail y. 
Refractory: low platelet count,
clinical deterioration. 
Begin ritux imab at 100-3 75 mg/m2 
week ly fo r 4 week s 
Remiss ion : no rmal plat elet counts
30 days after the last
plasmapheresis.
Relapse:  daily plasm apheres is with
plasm a exchange  plus  rituxim ab. 
Figure  1  Simplified  management  scheme  of  TTP.
continued  until  we  obtain  a number  higher  than  150 ×  109/L
platelets  and  normal  LDH.  After reaching  this  number,  the
case  is  monitored  daily  before  deciding  on  a  higher  plasma-
pheresis  sessions.  However,  in  hospitals  or  places  with  higher
economic  resources,  it is  reasonable  to  continue  with  at
least  2  plasmatic  exchanges  once  TTP remission  has  been
obtained.
The  use  of steroids  is  very  controversial.  No  benefits  have
been  clearly  demonstrated,  yet  they  are widely  used.
Rituximab
When  dealing  with  autoimmune  TTP,  it is  logical  to  use  an
antibody  whose  targets  are  the lymphocytes  B  responsible
for  the  immune  response  mediated  by  antibodies.  Such  is
the  case  with  rituximab,  whose  only objective  is  the antigen
CD20  on the  surface  of  the  lymphocytes  B.
The  use  of  rituximab  has  been  suggested  if there  is
cardiac  or  neurological  compromise.34 However,  its  use  in
all  patients  from  the  start  is  promising.  In an  acute  TTP
episode,  initial  treatment  with  rituximab,  plasmapheresis
and  corticosteroids  have  an apparent  remission  in  >90% of
the  patients  within  14  to  21  days  and  may  also  reduce  relapse
frequency.34
In patients  with  an  episode  of  refractory  TTP, the  addition
of  rituximab  to  plasmapheresis  and  corticosteroids  increases
platelet  counts  in >80%  of  the  patients  and  may  decrease  the
required  time  to  accomplish  a response  platelet  count.35
A persistent  severe  deficiency  of  ADAMTS13  during  remis-
sion  should  lead  to  the consideration  of  administering
rituximab  as  a  preventive  measure  to  avoid  relapse.36
In our  center,  we  published  4  cases  of  TTP  treated  with
low  doses  of  rituximab,  plasmapheresis  and  a short  steroid
course.  Patients  were  administered  100 mg of  rituximab
intravenously,  from  the  second  to  eighth  day,  with  the  begin-
ning  of  plasmapheresis  as  a first  line  therapy  in three  cases
and as  a rescue  therapy  for  relapses  in one  case.  The  number
of necessary  plasmaphereses  varied  from  5 to  12  sessions.
All  patients  reached  complete  remission  and  are currently
asymptomatic,  with  a duration  of  complete  response of  8--22
months.37 We  treated 7  more  patients  for a  total  of 11  and in
data  --  as  yet  unpublished  --  we  accomplished  a  disease-free
survival  rate  of 2  years  of  90%.  In Fig.  1  we  present  a scheme
showing  the  therapeutic  approach  of TTP in different  clinical
scenarios.
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New treatments
Recombinant  ADAMTS13
A  study  was  conducted  in  order  to  find  out  whether  or  not  an
ADAMTS13  recombinant  is  capable  of bearing  the neutraliz-
ing  antibodies  and  restoring  ADAMTS13  activity  in patients
with  acquired  TTP.  The  relationship  between  the  amount  of
added  ADAMTS13  recombinant,  the  recovery  of  ADAMTS13
activity  and  the  titles of  the  anti ADAMTS13  inhibitors  in the
patient  was  investigated.
They  demonstrated  that  an ADAMTS13  recombinant,  at
a  reasonable  dose,  has  the ability  to  bear  the neutraliz-
ing  inhibitors  and  rebuilding  ADAMTS13  in vitro  activity  in
acquired  TTP.38
Prognosis
Before  plasmapheresis,  TTP  had a mortality  rate  of  over  90%,
but  with  the  use  of  plasmapheresis  mortality  rate  went  down
to  20%.39 Despite  the major  advances  in the reduction  of
the  mortality  rate,  patients  who  survive  TTP  face  a series
of  challenges:  a major morbimortality  rate  compared  to  the
general  population,40 as  well  as  a lower  quality  of  life,  less
social  life  and cognitive  deficits,  in addition  to  the risk  of
relapse.41--44 Over a third  of patients  who  survive  an acute
episode  of TTP will  have  at least  a  relapse  during  the fol-
lowing  10  years.43 Relapse  rate  is  34%,  most  initial  relapses
among  patients  with  ADAMTS13  activity  <10%  occur  within
the  first  year  after  remission  and  this rate  decreases  with
time.44
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